Literature DB >> 28120410

Restrictive allograft syndrome and idiopathic pleuroparenchymal fibroelastosis: do they really have the same histology?

Maria A Montero1,2, Tina Osadolor2, Reena Khiroya1, Maria Teresa Salcedo3, Jan L Robertus1, Alexandra Rice1, Andrew G Nicholson1, Antonio Roman4, Victor Monforte4.   

Abstract

AIMS: Restrictive allograft syndrome (RAS) and idiopathic pleuroparenchymal fibroelastosis (IPPFE) are two different diseases reported to share the same histology. RAS relates to chronic allograft dysfunction in lung transplantation, with IPPFE being a rare condition in native lungs. Our aim is to compare their histologies alongside biopsies of usual interstitial pneumonia (UIP), to determine if there are differences that might help to elucidate the pathogenesis. METHODS AND
RESULTS: We selected four postmortem allograft lungs from patients who developed a clear clinical RAS pattern, five biopsies diagnosed as IPPFE, five UIP biopsies and five sections of normal lung. Histopathological features were described without knowledge of clinical and radiological features. Both RAS allografts and IPPFE biopsies showed intra-alveolar fibrosis and elastosis (IAFE), but RAS allografts also showed concomitant obliterative bronchiolitis, vascular lymphoplasmacytic inflammation within fibrointimal thickening, less fibroblastic foci (FF) at the advancing edge of the fibrosis (one against 14.4 FF in 2 mm2 ) and a slight reduction of the capillary network compared to UIP (P = 0.07) and controls (P = 0.06). The main differences seen in UIP were the lack of IAFE and the presence of honeycomb change.
CONCLUSIONS: RAS and PPFE histopathology both show IAFE, but display various differences, particularly in their vascular morphology that may allow further understanding of pathogenesis.
© 2017 John Wiley & Sons Ltd.

Entities:  

Keywords:  lung transplantion; obliterative bronchiolitis; pleuroparenchymal fibroelastosis; restrictive allograft syndrome

Mesh:

Year:  2017        PMID: 28120410     DOI: 10.1111/his.13171

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  7 in total

Review 1.  Chronic lung allograft dysfunction phenotypes and treatment.

Authors:  Stijn E Verleden; Robin Vos; Bart M Vanaudenaerde; Geert M Verleden
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

Review 2.  Diagnosis, Pathophysiology and Experimental Models of Chronic Lung Allograft Rejection.

Authors:  Jason M Gauthier; Daniel Ruiz-Pérez; Wenjun Li; Ramsey R Hachem; Varun Puri; Andrew E Gelman; Daniel Kreisel
Journal:  Transplantation       Date:  2018-09       Impact factor: 4.939

Review 3.  The pathogenesis and pathology of idiopathic pleuroparenchymal fibroelastosis.

Authors:  Yoshiaki Kinoshita; Hiroshi Ishii; Kazuki Nabeshima; Kentato Watanabe
Journal:  Histol Histopathol       Date:  2020-12-14       Impact factor: 2.303

Review 4.  Lung Transplantation: CT Assessment of Chronic Lung Allograft Dysfunction (CLAD).

Authors:  Anne-Laure Brun; Marie-Laure Chabi; Clément Picard; François Mellot; Philippe A Grenier
Journal:  Diagnostics (Basel)       Date:  2021-04-30

5.  Suspected pleuroparenchymal fibroelastosis relapse after lung transplantation: a case report and literature review.

Authors:  Edoardo Rasciti; Alessandra Cancellieri; Micaela Romagnoli; Andrea Dell'Amore; Maurizio Zompatori
Journal:  BJR Case Rep       Date:  2019-11-15

Review 6.  Pleuroparenchymal Fibroelastosis. A Review of Clinical, Radiological, and Pathological Characteristics.

Authors:  Felix Chua; Sujal R Desai; Andrew G Nicholson; Anand Devaraj; Elisabetta Renzoni; Alexandra Rice; Athol U Wells
Journal:  Ann Am Thorac Soc       Date:  2019-11

7.  Chronic lung allograft pathology lesions in two rat strain combinations.

Authors:  Federica Pezzuto; Francesca Lunardi; Marta Vadori; Davide Zampieri; Federica Casiraghi; Nadia Azzollini; Stefania Edith Vuljan; Marco Mammana; Luca Vedovelli; Marco Schiavon; Dario Gregori; Emanuele Cozzi; Federico Rea; Fiorella Calabrese
Journal:  J Thorac Dis       Date:  2021-05       Impact factor: 2.895

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.